title: Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I).
abstract: After initial surgery, 240 pre-, peri- or postmenopausal patients with early node-negative breast carcinoma were randomized to receive either no hormone therapy or adjuvant therapy with medroxyprogesterone acetate at high dosage (HD-MPA; 500 mg IM per day times 28 or 500 mg intramuscularly (i.m.) 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months. After a median follow-up time of 3 years, relapse-free survival and overall survival appeared significantly improved in the HD-MPA arm. Side effects were tolerable.
authors.affiliation: Clin. St Joseph-Ste Elisabeth, Liège, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Focan
authors.forename: A
authors.initials: A
authors.lastname: Baudoux
authors.forename: M
authors.initials: M
authors.lastname: Beauduin
authors.forename: U
authors.initials: U
authors.lastname: Bunescu
authors.forename: N
authors.initials: N
authors.lastname: Dehasque
authors.forename: L
authors.initials: L
authors.lastname: Dewasch
authors.forename: J P
authors.initials: JP
authors.lastname: Lobelle
authors.forename: E
authors.initials: E
authors.lastname: Longeval
authors.forename: F
authors.initials: F
authors.lastname: Majois
authors.forename: V
authors.initials: V
authors.lastname: Mazy
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D011897:Random Allocation
chemical_list: D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone